Can-Fite BioPharma Ltd.
CANF
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$0.19
Price-7.00%
-$0.01
1Y
Price
Market Cap
$2.001m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2413.4%
EBITDA Margin-2413.9%
Net Profit Margin-2353.0%
Free Cash Flow Margin-2413.4%
EBITDA Margin-2413.9%
Net Profit Margin-2353.0%
Free Cash Flow MarginRevenue
$560k
-16.9%
1y CAGR-11.5%
3y CAGR-9.9%
5y CAGREarnings
-$8.798m
-11.6%
1y CAGR+3.4%
3y CAGR+7.3%
5y CAGREPS
-$0.90
+16.7%
1y CAGR+36.2%
3y CAGR+40.8%
5y CAGRBook Value
$4.184m
$7.720m
Assets$3.536m
Liabilities$90k
DebtDebt to Assets
1.2%
-
Debt to EBITDAFree Cash Flow
-$8.355m
-9.3%
1y CAGR+7.4%
3y CAGR+3.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company